GlassScriptPhysician profile
Radhika Gupta
NPI 1255317103
$2,049.32
in general payments reported to CMS, 2019-2025
22 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.68 · 2020: $43.00 · 2021: $243 · 2022: $367 · 2023: $255 · 2024: $516 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $532.61 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $183.28 | 2021-2025 | |
| Lilly USA, LLC | $159.24 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Vanda Pharmaceuticals INC. | $156.06 | 2022-2023 | Hetlioz, Fanapt |
| Novo Nordisk INC | $142.69 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $138.56 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.47 | 2024-2025 | Jardiance |
| Amgen INC. | $113.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $88.14 | 2019-2024 | Shingrix, Arexvy |
| Pfizer INC. | $64.26 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $60.53 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $58.08 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $33.39 | 2022 | |
| Inspire Medical Systems, INC. | $29.86 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.90 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $25.14 | 2025 | Arikayce |
| Amarin Pharma, INC. | $24.88 | 2022 | |
| Abbott Laboratories | $19.87 | 2023 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $19.03 | 2019 | |
| Boston Scientific Corporation | $18.46 | 2021 | |
| Corcept Therapeutics | $17.50 | 2025 | Korlym |
| Dexcom, INC. | $15.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radhika Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.